Clinical bottom line
Male genital lichen planus (MGLP) is a chronic inflammatory mucocutaneous condition that can be refractory to conventional therapies, posing significant management challenges. Emerging novel therapies, including topical mucoadhesive corticosteroid formulations and biologically derived exosome treatments, show promise in improving clinical outcomes and tolerability in refractory cases. However, current evidence remains limited primarily to small case series and early-phase reports, warranting cautious interpretation. Clinicians should consider these novel options as adjuncts or alternatives in patients unresponsive to standard corticosteroid regimens, with careful monitoring for efficacy and safety.
What the evidence shows
MGLP is characterized by violaceous, polygonal papules and erosive lesions on the male genitalia, often causing pain, pruritus, and scarring that can impair quality of life (Hall et al., 2018). Standard treatment typically involves potent topical corticosteroids, but refractory disease is common, necessitating exploration of novel therapies (Kirtschig et al., 2023).
Recent advances include the development of mucoadhesive clobetasol propionate patches designed to enhance drug retention and local bioavailability. While data are primarily from erosive oral lichen planus, these formulations have demonstrated improved symptom control and safety profiles compared to conventional topical corticosteroids (Decision letter, 2021). This delivery system could be extrapolated to genital mucosa, offering a targeted approach with potentially fewer systemic effects.
Additionally, a recent single-patient case report documented histopathology-paired clinical improvement in long-standing refractory MGLP following topical application of Rosa damascena-derived exosomes, a novel biologic therapy with anti-inflammatory and regenerative properties (Kaniowski et al., 2026). This report suggests a putative mechanism for modulating local immune responses and promoting mucosal healing, although it remains preliminary.
Histopathological features of MGLP include a band-like lymphocytic infiltrate and basal cell degeneration, which are important for diagnosis and monitoring treatment response (Hall et al., 2018; Kirtschig et al., 2023). Novel therapies that modulate these pathological processes may offer improved outcomes over traditional corticosteroids, which primarily suppress inflammation but do not address tissue repair.
Caveats and uncertainty
The evidence base for novel therapies in refractory MGLP is limited by small sample sizes, lack of randomized controlled trials, and reliance on case reports or extrapolation from oral lichen planus studies. The mucoadhesive clobetasol patch, while promising, has not yet been rigorously evaluated in genital lichen planus populations, and differences in mucosal environment may affect efficacy and tolerability (Decision letter, 2021).
The single-patient exosome therapy report (Kaniowski et al., 2026) represents an intriguing hypothesis-generating observation but requires validation in larger cohorts with standardized outcome measures. Safety profiles, optimal dosing, and long-term effects of biologic exosome treatments remain unknown.
Furthermore, differentiation between MGLP and other genital dermatoses such as lichen sclerosus is critical, as therapeutic responses and prognoses differ (Kirtschig et al., 2023). Misclassification may confound interpretation of treatment efficacy.
How this may change practice
For urologists and dermatologists managing refractory MGLP, awareness of emerging topical delivery systems and biologic therapies expands the therapeutic armamentarium beyond conventional corticosteroids and immunosuppressants. Incorporating mucoadhesive corticosteroid patches may enhance local drug delivery and patient adherence, potentially improving symptom control with reduced adverse effects.
Biologic exosome therapies represent a novel, targeted approach that could shift treatment paradigms toward tissue regeneration and immune modulation rather than solely inflammation suppression. Pending further validation, these may be considered experimental options in specialized centers or clinical trials.
Clinicians should maintain a high index of suspicion for refractory MGLP and consider biopsy for histopathological confirmation and monitoring. Multidisciplinary collaboration with dermatology may optimize diagnosis and individualized treatment planning.